Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

Literature DB >> 30321404

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

Ravi A Madan¹, James L Gulley¹.

Abstract

Entities: Disease

Mesh：

Year: 2019 PMID： 30321404 PMCID： PMC6657437 DOI： 10.1093/jnci/djy145

Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506

× No keyword cloud information.

11 in total

1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Authors: John M Wrangle; Vamsidhar Velcheti; Manish R Patel; Elizabeth Garrett-Mayer; Elizabeth G Hill; James G Ravenel; Jeffrey S Miller; Mohammad Farhad; Kate Anderton; Kathryn Lindsey; Michele Taffaro-Neskey; Carol Sherman; Samantha Suriano; Marzena Swiderska-Syn; Amy Sion; Joni Harris; Andie R Edwards; Julie A Rytlewski; Catherine M Sanders; Erik C Yusko; Mark D Robinson; Carsten Krieg; William L Redmond; Jack O Egan; Peter R Rhode; Emily K Jeng; Amy D Rock; Hing C Wong; Mark P Rubinstein
Journal: Lancet Oncol Date: 2018-04-05 Impact factor: 41.316

2. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors: Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245

3. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors: Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal: Science Date: 2018-01-04 Impact factor: 47.728

4. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Authors: Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen
Journal: Lancet Oncol Date: 2014-05-13 Impact factor: 41.316

5. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Authors: Jianjun Gao; John F Ward; Curtis A Pettaway; Lewis Z Shi; Sumit K Subudhi; Luis M Vence; Hao Zhao; Jianfeng Chen; Hong Chen; Eleni Efstathiou; Patricia Troncoso; James P Allison; Christopher J Logothetis; Ignacio I Wistuba; Manuel A Sepulveda; Jingjing Sun; Jennifer Wargo; Jorge Blando; Padmanee Sharma
Journal: Nat Med Date: 2017-03-27 Impact factor: 53.440

Review 6. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors: Caroline Jochems; Jeffrey Schlom
Journal: Exp Biol Med (Maywood) Date: 2011-04-12

7. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Authors: Michael C Haffner; Gunes Guner; Diana Taheri; George J Netto; Doreen N Palsgrove; Qizhi Zheng; Liana Benevides Guedes; Kunhwa Kim; Harrison Tsai; David M Esopi; Tamara L Lotan; Rajni Sharma; Alan K Meeker; Arul M Chinnaiyan; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Rohit Mehra; Emmanuel S Antonarakis; Charles G Drake; Angelo M De Marzo
Journal: Am J Pathol Date: 2018-03-22 Impact factor: 4.307

8. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Authors: Tomasz M Beer; Guy T Bernstein; John M Corman; L Michael Glode; Simon J Hall; Wayne L Poll; Paul F Schellhammer; Lori A Jones; Yi Xu; Jelle W Kylstra; Mark W Frohlich
Journal: Clin Cancer Res Date: 2011-05-10 Impact factor: 12.531

Review 9. Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside.

Authors: Masahisa Jinushi; Yoshihiro Komohara
Journal: Biochim Biophys Acta Date: 2015-01-14

10. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors: Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal: Lancet Date: 2017-12-18 Impact factor: 79.321

6 in total

1. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.

Authors: Vincent T Ma; Christopher T Su; Miriam Hu; Jeremy M G Taylor; Stephanie Daignault-Newton; Olesia Kellezi; Megan N Dahl; Miloni A Shah; Stephanie Erickson; Jessica Lora; Reema Hamasha; Alicia Ali; Sabrina Yancey; Leah Kiros; Hannah M Balicki; Daniel C Winfield; Michael D Green; Ajjai S Alva
Journal: Urol Oncol Date: 2021-01-23 Impact factor: 2.954